{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:02:18Z","timestamp":1793444538876,"version":"4.5.0"},"reference-count":118,"publisher":"Georg Thieme Verlag KG","issue":"06","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Accurate measurement of clotting factors VIII (FVIII) or IX (FIX) is vital for comprehensive diagnosis and management of patients with hemophilia A or B. The one-stage activated partial thromboplastin time (aPTT)-based clotting assay is the most commonly used method worldwide for testing FVIII or FIX activities. Alternatively, FVIII and FIX chromogenic substrate assays, which assess the activation of factor X, are available in some specialized laboratories. The choice of reagent or methodology can strongly influence the resulting activity. Variation between one-stage FVIII or FIX activities has been reported in the measurement of some standard and extended half-life factor replacement therapies and gene therapy for hemophilia B using different aPTT reagents. Discrepancy between one-stage and chromogenic reagents has been demonstrated in some patients with mild hemophilia A or B, the measurement of some standard and extended half-life factor replacement therapies, and the transgene expression of hemophilia A and B patients who have received gene therapy. Finally, the measurement of bispecific antibody therapy in patients with hemophilia A has highlighted differences between chromogenic assays. It is imperative that hemostasis laboratories evaluate how suitable their routine assays are for the accurate measurement of the various hemophilia treatment therapies.<\/jats:p>","DOI":"10.1055\/s-0042-1758870","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T23:53:41Z","timestamp":1670370821000},"page":"609-620","source":"Crossref","is-referenced-by-count":39,"title":["Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments"],"prefix":"10.1055","volume":"49","author":[{"given":"Annette E.","family":"Bowyer","sequence":"additional","affiliation":[{"name":"Department of Coagulation, Royal Hallamshire Hospital, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Gosselin","sequence":"additional","affiliation":[{"name":"Hemostasis and Thrombosis Center, University of California, Davis Health System, Sacramento, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"A Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"G C White II","year":"2001","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs","volume":"236","author":"L M Aledort","year":"1994","journal-title":"J Intern Med"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"A Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A","volume":"12","author":"T E Coyle","year":"2014","journal-title":"J Thromb Haemost"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1055\/s-0037-1619772","article-title":"BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation","volume":"32","author":"P L Turecek","year":"2012","journal-title":"Hamostaseologie"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"J Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"24","key":"ref8","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"J S Powell","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"ref9","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"E Santagostino","year":"2016","journal-title":"Blood"},{"issue":"26","key":"ref10","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"P W Collins","year":"2014","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood-2019-124108","article-title":"Fitusiran, an RNAi therapeutic targeting antithrombin to restore hemostatic balance in patients with hemophilia A or B with or without inhibitors: management of acute bleeding events","volume":"134","author":"S W Pipe","year":"2019","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/ijlh.13605","article-title":"Gene therapy for hemophilia: current status and laboratory consequences","volume":"43","author":"P Batty","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have haemophilia A without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"ref14","first-page":"633","article-title":"Factor assay (VIII and IX) results in the College of American Pathologists Survey Program (1980-1982)","volume":"80","author":"R L Christensen","year":"1983","journal-title":"Am J Clin Pathol"},{"issue":"09","key":"ref15","first-page":"908","article-title":"Factors affecting the performance of factor VIII coagulant activity assays. Results of proficiency surveys of the College of American Pathologists","volume":"116","author":"C F Arkin","year":"1992","journal-title":"Arch Pathol Lab Med"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.1994.tb05028.x","article-title":"Proficiency testing of factor VIII:C activity assays at the Canadian Red Cross Society National Reference Laboratory","volume":"67","author":"S Wasi","year":"1994","journal-title":"Vox Sang"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1538-7836.2004.00657.x","article-title":"Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays","volume":"2","author":"J Ingerslev","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"e958","DOI":"10.1111\/j.1365-2516.2011.02523.x","article-title":"The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay","volume":"17","author":"C Pouplard","year":"2011","journal-title":"Haemophilia"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1055\/s-0037-1598058","article-title":"Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies","volume":"43","author":"S Kitchen","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"A C Weyand","year":"2019","journal-title":"Blood"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/ijlh.12877","article-title":"Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B","volume":"40","author":"D M Adcock","year":"2018","journal-title":"Int J Lab Hematol"},{"issue":"02","key":"ref22","first-page":"109","article-title":"Effect of lupus anticoagulants on the activated partial thromboplastin time. Results of the College of American Pathologists survey program","volume":"115","author":"J T Brandt","year":"1991","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.5858\/2004-128-1142-EOPFAD","article-title":"Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing","volume":"128","author":"R C Gosselin","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ijlh.13196","article-title":"The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays","volume":"42","author":"T Exner","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/hae.14536","article-title":"Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors' Organisation guideline","volume":"28","author":"A Bowyer","year":"2022","journal-title":"Haemophilia"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/hae.13005","article-title":"Alternative therapies for the management of inhibitors","volume":"22","author":"M Shima","year":"2016","journal-title":"Haemophilia"},{"issue":"06","key":"ref29","first-page":"793","article-title":"Activity of coagulation and fibrinolysis parameters in animals","volume":"44","author":"H E Karges","year":"1994","journal-title":"Arzneimittelforschung"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1136\/bmj.2.4799.1378","article-title":"Christmas disease: a condition previously mistaken for haemophilia","volume":"2","author":"R Biggs","year":"1952","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1600-0609.1984.tb02765.x","article-title":"Methodology of the two-stage assay of factor VIII (VIII:C)","volume":"41","author":"T W Barrowcliffe","year":"1984","journal-title":"Scand J Haematol Suppl"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2257.1980.tb00839.x","article-title":"Semi-automation of the two-stage factor VIII assay","volume":"2","author":"K WE Denson","year":"1980","journal-title":"Clin Lab Haematol"},{"issue":"04","key":"ref33","first-page":"637","article-title":"Effect of antihaemophilic factor on one-stage clotting tests. A presumptive assay for haemophilia and a simple antihaemophilic factor assay procedure","volume":"41","author":"R D Langdell","year":"1953","journal-title":"J Lab Clin Med"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijlh.12004","article-title":"Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis","volume":"35","author":"I Mackie","year":"2013","journal-title":"Int J Lab Hematol"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1365-2141.1999.01596.x","article-title":"Lipid composition of seven APTT reagents in relation to heparin sensitivity","volume":"106","author":"S Kitchen","year":"1999","journal-title":"Br J Haematol"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1751-553X.2010.01261.x","article-title":"The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies","volume":"33","author":"A Bowyer","year":"2011","journal-title":"Int J Lab Hematol"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ijlh.12499","article-title":"In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies","volume":"38","author":"P Toulon","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"ref38","first-page":"4","article-title":"The sensitivity of two new APTT reagents to factors VIII, IX and XI","author":"A E Bowyer","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.1984.tb02556.x","article-title":"Assay of factor VIII:C with a chromogenic substrate","volume":"40","author":"S Ros\u00e9n","year":"1984","journal-title":"Scand J Haematol Suppl"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/hae.13446","article-title":"Evaluation of chromogenic factor IX assays by automated protocols","volume":"24","author":"G W Kershaw","year":"2018","journal-title":"Haemophilia"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijlh.13083","article-title":"Performance evaluation of Revohem\u2122 FVIII chromogenic and Revohem\u2122 FIX chromogenic in the CS-5100 autoanalyser","volume":"41","author":"A Suzuki","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"ref45","first-page":"357","article-title":"Variant mild haemophilia: discrepancy in one-stage and two-stage factor VIII assays","volume":"50","author":"W E Hathaway","year":"1983","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1055\/s-0033-1334863","article-title":"Diagnostic testing for mild hemophilia a in patients with discrepant one-stage, two-stage, and chromogenic factor VIII:C assays","volume":"39","author":"E M Duncan","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1365-2141.2000.02021.x","article-title":"Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family","volume":"109","author":"R Schwaab","year":"2000","journal-title":"Br J Haematol"},{"issue":"12","key":"ref48","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3324\/haematol.2013.088088","article-title":"Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A","volume":"98","author":"A E Bowyer","year":"2013","journal-title":"Haematologica"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2516.2008.01899.x","article-title":"Assay discrepancy in mild haemophilia A: entire population study in a national haemophilia centre","volume":"15","author":"A L Poulsen","year":"2009","journal-title":"Haemophilia"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1160\/TH13-08-0690","article-title":"Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays","volume":"111","author":"A Pavlova","year":"2014","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V97.3.685","article-title":"Hemophilia A mutations associated with 1-stage\/2-stage activity discrepancy disrupt protein-protein interactions within the triplicated A domains of thrombin-activated factor VIIIa","volume":"97","author":"S W Pipe","year":"2001","journal-title":"Blood"},{"issue":"01","key":"ref52","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.V93.1.176","article-title":"Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo","volume":"93","author":"S W Pipe","year":"1999","journal-title":"Blood"},{"issue":"05","key":"ref53","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1055\/s-0037-1613302","article-title":"Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage\/two-stage activity discrepancy","volume":"88","author":"W H Hakeos","year":"2002","journal-title":"Thromb Haemost"},{"issue":"31","key":"ref54","doi-asserted-by":"crossref","first-page":"20095","DOI":"10.1016\/S0021-9258(17)32132-4","article-title":"Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage","volume":"269","author":"D A Michnick","year":"1994","journal-title":"J Biol Chem"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2141.2002.03617.x","article-title":"A Tyr346\u2013>Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy","volume":"118","author":"A D Mumford","year":"2002","journal-title":"Br J Haematol"},{"issue":"05","key":"ref56","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2141.2011.08688.x","article-title":"p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it","volume":"154","author":"A E Bowyer","year":"2011","journal-title":"Br J Haematol"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1365-2516.2007.01557.x","article-title":"Tyr346\u2013>Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A?","volume":"14","author":"H Lyall","year":"2008","journal-title":"Haemophilia"},{"issue":"08","key":"ref58","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1182\/blood.V73.8.2117.2117","article-title":"Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A","volume":"73","author":"D P O'Brien","year":"1989","journal-title":"Blood"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.V72.3.1022.1022","article-title":"Mutations of factor VIII cleavage sites in hemophilia A","volume":"72","author":"J Gitschier","year":"1988","journal-title":"Blood"},{"issue":"04","key":"ref60","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/hae.13219","article-title":"Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B","volume":"23","author":"K Kihlberg","year":"2017","journal-title":"Haemophilia"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2516.2008.01896.x","article-title":"Influence of source of phospholipids for APTT-based factor IX assays and potential consequences for the diagnosis of mild haemophilia B","volume":"15","author":"C Pouplard","year":"2009","journal-title":"Haemophilia"},{"issue":"05","key":"ref63","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2516.2002.00666.x","article-title":"A blinded in vitro study with Refacto mock plasma samples: similar FVIII results between the chromogenic assay and a one-stage assay when using a higher cephalin dilution","volume":"8","author":"C Caron","year":"2002","journal-title":"Haemophilia"},{"issue":"04","key":"ref64","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/hae.13123","article-title":"Measurement of B-domain-deleted ReFacto AF activity with a product-specific standard is affected by choice of reagent and patient-specific factors","volume":"24","author":"M Jacquemin","year":"2018","journal-title":"Haemophilia"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/s-2002-32659","article-title":"Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products","volume":"28","author":"M Mikaelsson","year":"2002","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref66","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/jth.13348","article-title":"Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study","volume":"14","author":"A E Bowyer","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref67","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/hae.12449","article-title":"Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays","volume":"20","author":"H V Wilmot","year":"2014","journal-title":"Haemophilia"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/hae.13907","article-title":"Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: a United Kingdom Haemophilia Centre Doctors' Organisation guideline","volume":"26","author":"E Gray","year":"2020","journal-title":"Haemophilia"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"P H Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"issue":"11","key":"ref71","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1182\/blood-2012-01-407494","article-title":"A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models","volume":"121","author":"H R Stennicke","year":"2013","journal-title":"Blood"},{"issue":"08","key":"ref72","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2011-02-336172","article-title":"Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide","volume":"118","author":"H \u00d8stergaard","year":"2011","journal-title":"Blood"},{"issue":"04","key":"ref73","first-page":"634","article-title":"Genetic fusion to albumin improves the pharmacokinetic properties of factor IX","volume":"102","author":"H J Metzner","year":"2009","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref74","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood-2012-05-429688","article-title":"Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients","volume":"120","author":"E Santagostino","year":"2012","journal-title":"Blood"},{"key":"ref75","first-page":"124","article-title":"Chromogenic and one stage FIX assays in the presence of Idelvion (rFIXFP), Alprolix (rFIXFc), Benefix and Replenine: data from a UK NEQAS for Blood Coagulation Survey (OC 65.2)","volume":"1","author":"S Kitchen","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"ref76","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2009-08-239665","article-title":"Prolonged activity of factor IX as a monomeric Fc fusion protein","volume":"115","author":"R T Peters","year":"2010","journal-title":"Blood"},{"issue":"03","key":"ref77","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2011-07-367003","article-title":"Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1\/2a study in hemophilia B patients","volume":"119","author":"A D Shapiro","year":"2012","journal-title":"Blood"},{"issue":"08","key":"ref78","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.14847","article-title":"Performance of factor IX extended half-life product measurements in external quality control assessment programs","volume":"18","author":"A Nederlof","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref79","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/jth.14332","article-title":"Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays","volume":"17","author":"C Horn","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref80","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/jth.13375","article-title":"Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP","volume":"14","author":"W Pickering","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref81","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/hae.13168","article-title":"Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study","volume":"23","author":"A Hillarp","year":"2017","journal-title":"Haemophilia"},{"issue":"05","key":"ref82","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/hae.13564","article-title":"Factor VIII activity of BAY 94-9027 is accurately measured with most commonly used assays: results from an international laboratory study","volume":"24","author":"N Church","year":"2018","journal-title":"Haemophilia"},{"issue":"05","key":"ref83","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1111\/hae.13290","article-title":"The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate","volume":"23","author":"A Bowyer","year":"2017","journal-title":"Haemophilia"},{"issue":"03","key":"ref84","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jth.13932","article-title":"International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories","volume":"16","author":"K St Ledger","year":"2018","journal-title":"J Thromb Haemost"},{"key":"ref85","author":"Afstyla"},{"issue":"11","key":"ref86","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"B A Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"ref87","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1182\/blood-2011-02-335596","article-title":"Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B","volume":"118","author":"C Negrier","year":"2011","journal-title":"Blood"},{"issue":"10","key":"ref88","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1111\/jth.13787","article-title":"Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol","volume":"15","author":"S Tiefenbacher","year":"2017","journal-title":"J Thromb Haemost"},{"key":"ref89","first-page":"60","article-title":"Performance of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in the one-stage assay","volume":"22","author":"K Ledger","year":"2016","journal-title":"Haemophilia"},{"issue":"05","key":"ref90","first-page":"932","article-title":"Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity","volume":"112","author":"J M Sommer","year":"2014","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref91","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1111\/ijlh.12953","article-title":"Measurement of extended half-life recombinant factor IX products in clinical practice","volume":"41","author":"A E Bowyer","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"06","key":"ref92","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/jth.14784","article-title":"Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays","volume":"18","author":"F Peyvandi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref93","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/ejh.13423","article-title":"Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: guidelines from the French BIMHO group (GFHT)","volume":"105","author":"E Jeanpierre","year":"2020","journal-title":"Eur J Haematol"},{"issue":"10","key":"ref94","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"T Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"06","key":"ref95","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jth.15682","article-title":"A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys","volume":"20","author":"B Lauritzen","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"23","key":"ref97","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"P J Lenting","year":"2017","journal-title":"Blood"},{"key":"ref98","first-page":"49","article-title":"The effect of emicizumab on assays of factor VIII activity in severe haemophilia A patients and artificially spiked plasma (PO27)","volume":"25","author":"A E Bowyer","year":"2019","journal-title":"Haemophilia"},{"issue":"07","key":"ref99","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"J I Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"key":"ref101","first-page":"4","article-title":"Effect of emicizumab (ACE910) \u2013 a humanized bispeci\ufb01c antibody mimicking FVIII cofactor function \u2013 on coagulation assays commonly in use for monitoring of hemophilia A patients","volume":"23","author":"J Adamkewicz","year":"2017","journal-title":"Haemophilia"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/hae.13903","article-title":"Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline","volume":"26","author":"P V Jenkins","year":"2020","journal-title":"Haemophilia"},{"issue":"02","key":"ref104","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1515\/cclm-2020-0696","article-title":"Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma","volume":"59","author":"A Tripodi","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"04","key":"ref105","doi-asserted-by":"crossref","first-page":"O204","DOI":"10.1111\/ijlh.13518","article-title":"Measurement of antifactor VIII antibody titre in the presence of emicizumab; use of chromogenic Bethesda assays","volume":"43","author":"A Bowyer","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JBM.S159297","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B","volume":"9","author":"N Machin","year":"2018","journal-title":"J Blood Med"},{"issue":"22","key":"ref107","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"A D Shapiro","year":"2019","journal-title":"Blood"},{"issue":"05","key":"ref108","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/hae.13820","article-title":"Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas","volume":"25","author":"S Patel-Hett","year":"2019","journal-title":"Haemophilia"},{"issue":"05","key":"ref109","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","article-title":"Targeting activated protein C to treat hemophilia","volume":"24","author":"S GI Polderdijk","year":"2017","journal-title":"Curr Opin Hematol"},{"issue":"05","key":"ref110","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/hae.13816","article-title":"Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia","volume":"25","author":"F Peyvandi","year":"2019","journal-title":"Haemophilia"},{"issue":"09","key":"ref112","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/14712598.2022.2002842","article-title":"Hemophilia A gene therapy: current and next-generation approaches","volume":"22","author":"S W Pipe","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"26","key":"ref114","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"S Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2019-122143","article-title":"Updated follow-up of the Alta Study, a phase 1\/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult patients with severe hemophilia A [abstract]","volume":"134","author":"B A Konkle","year":"2019","journal-title":"Blood"},{"issue":"01","key":"ref116","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"K J Pasi","year":"2020","journal-title":"N Engl J Med"},{"key":"ref117","first-page":"303","article-title":"Factor VIII clotting and chromogenic activities for TAK- 754 \/ SHP654, a clinical hemophilia A gene therapy candidate, using in vitro and in vivo assays","volume":"3","author":"J Lengler","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"04","key":"ref118","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1365-2516.1998.440646.x","article-title":"Influence of phospholipids on the assessment of factor VIII activity","volume":"4","author":"M Mikaelsson","year":"1998","journal-title":"Haemophilia"},{"issue":"22","key":"ref119","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"S Rosen","year":"2020","journal-title":"Blood"},{"issue":"17","key":"ref120","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"P Simioni","year":"2009","journal-title":"N Engl J Med"},{"issue":"05","key":"ref121","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/jth.15281","article-title":"Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua","volume":"19","author":"M M Robinson","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref122","first-page":"x","article-title":"Multi-centre field study of one-stage and chromogenic factor IX assays in samples containing the factor IX Padua variant","volume":"4","author":"J H Foley","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref123","first-page":"x","article-title":"Mechanistic evaluation of factor IX-Padua activity in chromogenic FIX and thrombin generation assays","volume":"4","author":"E Shehu","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood-2018-99-119616","article-title":"Activity of a FIX-Padua transgene product in commonly used FIX:C one-stage and chromogenic assay systems following PF-06838435 (SPK-9001) gene delivery","volume":"132","author":"M Robinson","year":"2018","journal-title":"Blood"},{"issue":"06","key":"ref125","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1055\/s-0038-1650691","article-title":"Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M","volume":"76","author":"C Lee","year":"1996","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref126","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-2516.1998.440634.x","article-title":"Discrepancies in potency assessment of recombinant FVIII concentrates","volume":"4","author":"T W Barrowcliffe","year":"1998","journal-title":"Haemophilia"},{"issue":"02","key":"ref127","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/hae.12296","article-title":"Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories","volume":"20","author":"J M Sommer","year":"2014","journal-title":"Haemophilia"},{"key":"ref128","first-page":"PB0679","article-title":"Measuring the chromogenic FVIII mimetic activity of the new bispecific antibody, Mim8, in artificially spiked severe haemophilia A plasma","author":"A E Bowyer","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref129","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1538-7836.2007.02861.x","article-title":"Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype","volume":"6","author":"M Trossa\u00ebrt","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref130","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/hae.13520","article-title":"Role of chromogenic assays in haemophilia A and B diagnosis","volume":"24","author":"A E Bowyer","year":"2018","journal-title":"Haemophilia"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1758870.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T15:44:56Z","timestamp":1701531896000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1758870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":118,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2023,8,11]]},"published-print":{"date-parts":[[2023,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1758870","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]}}}